Novo Nordisk A/S Sponsored ADR (NVO)
Novo Nordisk says it's not immune to potential Trump tariffs, but business is well-positioned
Wegovy maker Novo Nordisk is not immune to tariffs U.S. President Donald Trump is threatening to levy on the European Union, its chief executive said on Wednesday, but it is confident its business is well-positioned.
Novo Nordisk sales beat estimates, but the story wasn't Ozempic
Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn't its wildly popular weight-loss drugs.
Novo Nordisk's new CagriSema study to focus on dose escalation and trial length
Novo Nordisk on Wednesday said its new trial of its next-generation obesity drug candidate CagriSema will look at dose escalation and trial length to further show the drug's potential, after data in December disappointed the market.
Novo Nordisk shares surge as Wegovy sales drive profit beat
Shares of Novo Nordisk climbed 4.5% on Wednesday after the Danish pharmaceutical giant reported a stronger-than-expected fourth-quarter net profit, driven by soaring demand for its obesity treatment, Wegovy. However, the company warned that sales growth could slow in 2025 as competition intensifies in the weight-loss drug market.
Novo Nordisk Stock Rises After Earnings Beat. There Are Some Growth Concerns.
The weight-loss drugmaker's Wegovy and Ozempic are among the most closely watched new medications in recent history, but face serious competition from Eli Lilly's Zepbound and Mounjaro.
Novo Nordisk reports strong Q4 profits but warns of slower growth in 2025
Novo Nordisk (NYSE:NVO) posted a better-than-expected net profit of 28.23 billion Danish kroner ($3.98 billion) in the fourth quarter, beating analyst forecasts. The company's blockbuster Wegovy obesity drug saw sales soar 107% year-on-year to 19.87 billion Danish kroner ($2.76 billion), though this was slightly below expectations.
Novo Nordisk to seek regulatory approval for CagriSema obesity drug early 2026
Novo Nordisk said on Wednesday it plan to file its experimental next-generation obesity drug CagriSema for regulatory approval during the first quarter of next year, slightly later than its previous expectation to file towards end-2025.
Wegovy maker Novo Nordisk says surging growth driving emissions higher
Novo Nordisk emissions grew 23% in 2024, the company said on Wednesday, and will keep rising through the end of the decade as it boosts production of blockbuster obesity drug Wegovy.
Novo Nordisk posts net profit beat as Wegovy sales jump 107% in fourth quarter
Novo Nordisk posts net profit beat as Wegovy sales jump 107% in fourth quarter
Novo Nordisk Q4 profit beats expectations, sees slower growth in 2025
Weight-loss and diabetes drugmaker Novo Nordisk on Wednesday posted fourth-quarter operating profit above expectations as it forecast sales to grow at a slower pace in 2025 than last year.
Novo Nordisk Stock Slides Before Q4 Earnings: Analysts Still See 68% Upside
Novo Nordisk A/S NVO will report its fourth-quarter earnings on Wednesday. Wall Street expects 86 cents in EPS and $11.40 billion in revenues as the company reports before market hours.
Focus: Investors seek answers on Novo Nordisk's next-gen obesity drug CagriSema
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid a lack of clarity over trial results that hammered its shares in December.
